CompletedPhase 2NCT04937907
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
Studying Alport syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Children's Hospital
- Principal Investigator
- Wen-yan Huang, PhDShanghai Children's Hospital
- Intervention
- Hydroxychloroquine Sulfate 100 milligram (mg) Tab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- Shanghai Children's Hospital, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04937907 on ClinicalTrials.govOther trials for Alport syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07211685BAY3401016; Biomarker Study AlportBayer
- ACTIVE NOT RECRUITINGPHASE4NCT06499948Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)Stefan Lujinschi
- ACTIVE NOT RECRUITINGNCT06226896Effects of Dapagliflozin on Progression of Alport SyndromeNanjing University School of Medicine
- RECRUITINGNCT06526741ASF Alport Patient RegistryAlport Syndrome Foundation
- ACTIVE NOT RECRUITINGPHASE2NCT04573920Atrasentan in Patients With Proteinuric Glomerular DiseasesNovartis Pharmaceuticals
- RECRUITINGNCT04947813Genotype-Phenotype Correlations in Patients With Alport SyndromeXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT05927467Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02378805Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeUniversity Hospital Goettingen